Indeed, this overlap between the ECS and PPAR signaling makes the coupling of PPAR agonism with the enhancement of endocannabinoid tone (e.g., through FAAH inhibition) a very interesting avenue of research for novel pharmaceuticals, whose applications would range from the treatment of cancer [15], to neurodegenerative diseases [16], and alcohol withdrawal [17], other than merely for metabolic syndrome. The gene discussed is FAAH; the disease is cancer.